The current study revealed that the ABCG2 C421A (rs2231142) polymorphism significantly impacted both the plasma trough concentration and molecular response to imatinib in Egyptian patients with chronic-phase CML. Here, ABCG2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.